ABEMACARE: Abemaciclib in combination with endocrine therapy as first line therapy in metastatic breast cancer patients with symptomatic visceral metastases or high tumor burden

Kotzur F, Bidner H, Bronger H, Egert S, Fasching P, Fischer D, Kehl V, Luck HJ, Muller L, Reuning U, Rief L, Rosch R, Seitz S, Winter C, Kiechle M, Ettl J (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Cancer Research American Association for Cancer Research

Publisher: AMER ASSOC CANCER RESEARCH

City/Town: PHILADELPHIA

Conference Proceedings Title: CANCER RESEARCH

DOI: 10.1158/1538-7445.sabcs20-ot-26-01

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Technische Universität München (TUM) DE Germany (DE) Humboldt-Universität zu Berlin DE Germany (DE) Universitätsklinikum Regensburg DE Germany (DE)

How to cite

APA:

Kotzur, F., Bidner, H., Bronger, H., Egert, S., Fasching, P., Fischer, D.,... Ettl, J. (2021). ABEMACARE: Abemaciclib in combination with endocrine therapy as first line therapy in metastatic breast cancer patients with symptomatic visceral metastases or high tumor burden. In CANCER RESEARCH. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.

MLA:

Kotzur, Franziska, et al. "ABEMACARE: Abemaciclib in combination with endocrine therapy as first line therapy in metastatic breast cancer patients with symptomatic visceral metastases or high tumor burden." Proceedings of the CANCER RESEARCH PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2021.

BibTeX: Download